Two problematic drugs for diabetes associated with worrying side effects could reduce the risk of patients developing Parkinson's evil, a fact that would offer a springboard for future research, as several scientists explain.
An analysis of more than 160,000 British diabetics found that those who took Rosiglitazona or Pioglitazone had 28 percent less incidence of Parkinson's than people who underwent other diabetes treatments.
The two medications, whose patents are no longer in force, were developed by Glaxosmithkline and Takeda, respectively, and sold with the Avandia and acts marks.The use of rosiglitazone was suspended for the worrying heart effects it behaved, although the restrictions later rose, while the pioglitazone generated fears of a possible relationship with bladder cancer.
The scientists, who published their findings in the specialized magazine PLOS Medicine, do not recommend the use of these drugs to directly treat Parkinson's, but say that the biological roads that activate should be explored in future research.
"We often listen to things about possible negative side effects associated with medication, but sometimes there may be unwanted beneficial effects," said researcher Ian Douglas at the School of Hygiene and Tropical Medicine in London.
"Our findings provide unique evidence that we hope can promote future research on the potential treatments of Parkinson's evil," he added.
The study was funded by the Michael J Fox Foundation for research on Parkinson.It only included patients with diabetes who had not been diagnosed with Parkinson and therefore could not demonstrate whether to take the drugs made slower or avoided the progress of degenerative brain disease.
Another recently published clinical test found that it was likely that pioglitazone did not modify the advance in the early stages of Parkinson.